Affinage

CEBPD

CCAAT/enhancer-binding protein delta · UniProt P49716

Length
269 aa
Mass
28.5 kDa
Annotated
2026-06-09
100 papers in source corpus 35 papers cited in narrative 35 extracted findings
Cross-family judge vs UniProt: tie faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

CEBPD (C/EBPδ, NF-IL6-β) is a stimulus-inducible bZIP transcription factor that translates inflammatory, metabolic, and stress signals into changes in target-gene transcription (PMID:7680115, PMID:8385337). It functions through leucine-zipper-mediated dimerization, forming homodimers and heterodimers with C/EBPβ (NF-IL6) that bind C/EBP DNA elements and synergistically transactivate target promoters (PMID:1741402); it likewise pairs with PU.1 via its leucine zipper to co-occupy adjacent DNA sites (PMID:7594592), and synthetic leucine-zipper decoy peptides that block CEBPD dimer formation suppress its transcriptional output (PMID:34065488). CEBPD is transcriptionally induced by IL-6 and IL-1 to drive acute-phase and inflammatory gene expression including complement C3, haptoglobin, and COX-2 (PMID:7680115, PMID:8385337, PMID:11668179), with its induction gated by p38 MAPK signaling — which both controls CEBPD synthesis and docks on a CEBPD transactivation domain (residues ~70–108) to phosphorylate it (PMID:11668179, PMID:15694370) — and terminated by Miz1-directed HDAC1 recruitment to the CEBPD gene (PMID:23525087). Its own activity is further tuned by post-translational control: SUMO1 modification at lysine 120 converts CEBPD into a repressor that recruits HDAC1 and HDAC3 to silence target promoters such as PPARG2 (PMID:18619497), while ubiquitin-dependent proteasomal turnover limits its abundance (PMID:12554732). CEBPD enforces G0 growth arrest and acts as a tumor suppressor by inducing the APC/C subunit CDC27 to drive cyclin D1 polyubiquitination and degradation (PMID:9045647, PMID:20439707). Beyond transcription, CEBPD has a transcription-independent role in DNA repair, bridging FANCD2 to importin-4 (IPO4) to promote FANCD2 nuclear import required for its monoubiquitination (PMID:20805509). In cancer contexts CEBPD is context-dependent, conferring chemoresistance through transcriptional activation of SOD1, the drug transporters ABCB1/ABCC2, and PRKDC (PMID:20385105, PMID:27435393, PMID:32661323), promoting hypoxia-driven invasion and angiogenesis via HIF/VEGF-C and FN1 axes (PMID:21666710, PMID:37059730), and shaping NK-cell anti-tumor function and metabolic fitness (PMID:39137729).

Mechanistic history

Synthesis pass · year-by-year structured walk · 26 steps
  1. 1992 High

    Established the biochemical basis of CEBPD action by showing it is a bZIP factor that dimerizes and binds C/EBP DNA elements, defining how it engages the genome.

    Evidence In vitro heterodimerization, EMSA, and luciferase reporter assays with C/EBPβ

    PMID:1741402

    Open questions at the time
    • Did not define physiological stimuli or endogenous target genes
    • Relative roles of homo- vs heterodimers in vivo unresolved
  2. 1993 High

    Showed CEBPD is itself transcriptionally induced by inflammatory cytokines and directs acute-phase gene transcription, placing it downstream of IL-6/IL-1 signaling.

    Evidence Nuclear binding assays, EMSA/supershift, and reporter/mutagenesis at IL-6RE and complement C3 promoter in Hep3B cells

    PMID:7680115 PMID:8385337

    Open questions at the time
    • Upstream signal-transduction steps not yet mapped
    • Did not address post-translational regulation of CEBPD
  3. 1995 High

    Identified PU.1 as a direct CEBPD partner and mapped the interacting domains, extending the dimerization logic to cross-family transcriptional synergy.

    Evidence Far Western, deletion mutagenesis, EMSA, and reporter assays

    PMID:7594592

    Open questions at the time
    • Target genes of the CEBPD/PU.1 pair not defined
    • Cell-type specificity of the interaction unaddressed
  4. 1997 Medium

    Defined a cell-cycle function by showing CEBPD induction is required to initiate G0 growth arrest, linking it to growth suppression.

    Evidence Antisense CEBPD with cell-cycle analysis in growth-arrested mammary epithelial cells

    PMID:9045647

    Open questions at the time
    • Molecular effectors of arrest not yet identified
    • Antisense approach lacks single-gene specificity controls
  5. 2001 High

    Distinguished CEBPD from C/EBPβ functionally by showing it is specifically required for the sustained phase of inflammatory COX-2 induction downstream of MAPK/p38.

    Evidence C/EBPβ knockout macrophages, MAPK/p38 inhibitors, and COX-2 induction assays

    PMID:11668179

    Open questions at the time
    • Direct phosphorylation events not yet mapped
    • Did not address transcriptional vs post-translational contributions
  6. 2003 Medium

    Revealed that CEBPD abundance is constrained by ubiquitin-dependent nuclear degradation and short mRNA half-life, explaining its transient, immediate-early behavior.

    Evidence Pulse-chase, RACE-PAT, and proteasome inhibitor experiments in mammary epithelial cells

    PMID:12554732

    Open questions at the time
    • E3 ligase responsible not identified
    • Degron sequences not mapped
  7. 2005 Medium

    Mapped a bifunctional CEBPD domain that both transactivates and docks p38 MAPK, providing a structural basis for signal-dependent activation.

    Evidence Domain mutagenesis, p38 inhibitor, and reporter assays for haptoglobin induction

    PMID:15694370

    Open questions at the time
    • Phosphoacceptor residues not pinpointed
    • Single-lab biochemistry without structural confirmation
  8. 2008 High

    Showed SUMO1 modification at K120 acts as a molecular switch converting CEBPD from activator to HDAC-recruiting repressor, explaining bidirectional control of target genes.

    Evidence Sumoylation assays, K120 mutagenesis, Co-IP with HDAC1/3, and ChIP/reporter at PPARG2 in HepG2 cells

    PMID:18619497

    Open questions at the time
    • SUMO ligase/desumoylase enzymes not identified
    • Genome-wide scope of suCEBPD repression unknown
  9. 2010 High

    Connected CEBPD to the cell-cycle machinery mechanistically by showing it induces APC/C subunit CDC27 to drive cyclin D1 degradation, establishing a tumor-suppressive pathway.

    Evidence Knockout MEFs, siRNA, ChIP, reporter, and Western blot

    PMID:20439707

    Open questions at the time
    • In vivo tumor-suppressor role not tested here
    • Crosstalk with GSK-3β pathway only partially defined
  10. 2010 High

    Uncovered a transcription-independent role: CEBPD chaperones FANCD2 into the nucleus via IPO4, a prerequisite for FANCD2 monoubiquitination in DNA repair.

    Evidence Reciprocal Co-IP mapping separate domains, KO MEFs, siRNA, nuclear fractionation, and mitomycin C survival assays

    PMID:20805509

    Open questions at the time
    • Structural basis of the FANCD2–CEBPD–IPO4 ternary complex unknown
    • Whether this activity is regulated by the same signals as transcription unclear
  11. 2010 Medium

    Demonstrated context-dependent pro-survival and pro-resistance activity by showing CEBPD transactivates SOD1 to reduce chemotherapy-induced ROS and apoptosis.

    Evidence Reporter, ChIP, ROS/apoptosis assays, and siRNA in bladder urothelial carcinoma cells

    PMID:20385105

    Open questions at the time
    • Reconciliation with tumor-suppressor role not addressed
    • Single tumor-cell context
  12. 2010 Medium

    Extended CEBPD into innate-immune and tissue functions through direct regulation of TLR8 and astrocytic PTX3.

    Evidence ChIP and reporter assays (TLR8); gene profiling, ChIP, siRNA, and phagocytosis assay (PTX3)

    PMID:20829351 PMID:21112127

    Open questions at the time
    • In vivo immune phenotypes not established
    • Stimulus-specific binding mechanism at TLR8 unclear
  13. 2010 Medium

    Showed CEBPD opposes RB/E2F1 repression of growth-arrest gene promoters and is itself induced via the p38/CREB pathway, reinforcing its anti-proliferative axis.

    Evidence ChIP, reporter assays, p38/CREB inhibitors, and xenograft model

    PMID:20971808

    Open questions at the time
    • Direct CEBPD–RB/E2F1 biochemical relationship not defined
    • Single-lab data
  14. 2011 High

    Identified Miz1/HDAC1 as the off-switch that terminates LPS-induced CEBPD transcription, defining how inflammatory CEBPD output is temporally bounded in vivo.

    Evidence Miz1 POZ-domain mutant mice, phosphorylation mapping, HDAC1 recruitment, and in vivo LPS challenge

    PMID:23525087

    Open questions at the time
    • Kinase phosphorylating Miz1 Ser178 not identified
    • Generality beyond LPS inflammation untested
  15. 2011 Medium

    Linked CEBPD to hypoxia-driven lymphangiogenesis through a reciprocal HIF-1α loop controlling VEGF-C/VEGFR3.

    Evidence Mouse genetic deletion, LEC gain/loss-of-function, tube formation, and in vivo lymphangiogenesis assays

    PMID:21666710

    Open questions at the time
    • Mechanism of CEBPD regulation of HIF-1α not resolved
    • Single-lab functional data
  16. 2011 Medium

    Showed CEBPD can act as a tissue-specific repressor by interacting with Pit1 to suppress prolactin and downregulating proliferation drivers in pituitary tumor cells.

    Evidence siRNA, forced expression, ChIP, reporter, and microarray profiling

    PMID:21980073

    Open questions at the time
    • CEBPD–Pit1 interaction interface not mapped
    • In vivo tumor relevance untested
  17. 2012 Medium

    Defined a cytoprotective role in pancreatic beta-cells where CEBPD restrains CHOP/BIM-mediated apoptosis and dampens chemokine output, refining its context-dependence.

    Evidence siRNA, overexpression, and caspase/apoptosis assays in rat and human islet cells

    PMID:22347430

    Open questions at the time
    • Direct CEBPD targets in this circuit not all identified
    • Single-lab data
  18. 2016 Medium

    Established a chemoresistance pathway in which EGFR/STAT3 drive CEBPD to activate ABCB1/ABCC2 drug transporters, conferring cross-resistance.

    Evidence siRNA/shRNA, reporter, ChIP, xenograft, and pharmacological inhibitors in bladder carcinoma

    PMID:27435393

    Open questions at the time
    • Whether STAT3 directly co-regulates the transporter promoters with CEBPD unclear
    • Single tumor type
  19. 2017 Medium

    Showed metformin stabilizes CEBPD (via reduced Src degradation and AMPK activation), which then induces autophagy genes LC3B and ATG3, linking CEBPD to autophagy-coupled apoptosis.

    Evidence Reporter, ChIP, siRNA, AMPK modulators, and apoptosis assays in hepatocellular carcinoma cells

    PMID:28099155

    Open questions at the time
    • Src-mediated degradation mechanism not detailed
    • Single-lab data
  20. 2019 Medium

    Confirmed CEBPD as a druggable dimerization target by showing a dominant-negative leucine-zipper peptide binds CEBPD and suppresses its activity selectively in cancer cells.

    Evidence MS-based pulldown, immunoblotting, knockdown, and reporter assays

    PMID:31676720

    Open questions at the time
    • Endogenous binding partners displaced by DN-ATF5 not fully mapped
    • Selectivity mechanism for cancer cells unclear
  21. 2020 Medium

    Extended the IPO4–CEBPD axis to chemoresistance by showing IPO4-driven nuclear import of CEBPD enables transcriptional upregulation of PRKDC for cisplatin-induced DNA repair.

    Evidence shRNA, reporter, ChIP, DNA-repair assays, and xenograft

    PMID:32661323

    Open questions at the time
    • NLS residues of CEBPD recognized by IPO4 not fully defined
    • Single-lab data
  22. 2021 Medium

    Identified BRD4 (bromodomain-1) as a chromatin reader required for CEBPD expression and a direct CEBPD co-factor in vascular smooth muscle inflammation.

    Evidence ChIP-seq, genomic deletion, BRD4 silencing, reciprocal Co-IP, and JQ1 inhibition

    PMID:33768129

    Open questions at the time
    • Structural basis of BRD4 bromodomain-1 specificity not resolved
    • Single-lab data
  23. 2021 Medium

    Showed multiple cancer/stromal circuits route through CEBPD: post-transcriptional control via PUM2 SUMOylation driving DSG2/vasculogenic mimicry, and CAF-derived SDF4 driving CXCR4/VEGFD angiogenesis, plus AR-driven CEBPD→CASP8 control of apoptosis.

    Evidence Co-IP, RIP, ChIP, reporter assays, and in vivo angiogenesis/vasculogenic mimicry models

    PMID:24810056 PMID:32997416 PMID:33953165

    Open questions at the time
    • Integration of these parallel circuits in a single tumor unclear
    • Each from a single lab/context
  24. 2021 Medium

    Validated leucine-zipper decoy peptides (Dpep/Bpep) as CEBPD-disrupting agents that suppress direct targets (IL6, IL8, ASNS) and trigger cancer-selective apoptosis.

    Evidence Cell-penetrating peptides, reporter, Western blot, apoptosis assays, and xenografts

    PMID:34065488

    Open questions at the time
    • Off-target effects on other bZIP factors not fully excluded
    • Pharmacokinetics/in vivo delivery not optimized
  25. 2023 Medium

    Defined a hypoxia-to-invasion cascade where HIF1α/HIF2α induce CEBPD, which activates FN1 to drive EGFR/PI3K-dependent glioblastoma invasion.

    Evidence ChIP-seq/qPCR, luciferase reporter, knockdown, and in vitro/in vivo invasion assays

    PMID:37059730

    Open questions at the time
    • Relative contribution of HIF1α vs HIF2α not resolved
    • Single tumor model
  26. 2024 Medium

    Established CEBPD as a master regulator of engineered NK-cell anti-tumor function and metabolic fitness, expanding its role into immune-effector programming.

    Evidence CRISPR deletion, overexpression, ATAC-seq, and in vivo GBM models with cytotoxicity assays

    PMID:39137729

    Open questions at the time
    • Direct CEBPD target genes underpinning NK metabolic fitness not enumerated
    • Single-lab data

Open questions

Synthesis pass · forward-looking unresolved questions
  • How CEBPD's opposing roles — tumor-suppressive G0 arrest versus pro-survival chemoresistance, invasion, and angiogenesis — are selected within a given cell state remains unresolved.
  • No unified model integrating SUMO/phosphorylation/degradation switches with context-specific output
  • Structural basis of dimer-partner choice and its functional consequences undefined
  • In vivo dose-dependence of CEBPD tumor-suppressor vs oncogenic behavior unmapped

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140110 transcription regulator activity 4 GO:0003677 DNA binding 3 GO:0140104 molecular carrier activity 1
Localization
GO:0005634 nucleus 4
Pathway
R-HSA-74160 Gene expression (Transcription) 4 R-HSA-1643685 Disease 3 R-HSA-168256 Immune System 3 R-HSA-1640170 Cell Cycle 2 R-HSA-73894 DNA Repair 2
Partners
BRD4CEBPBFANCD2HDAC1HDAC3IPO4PIT1PU.1

Evidence

Reading pass · 35 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1992 CEBPD (NF-IL6-beta) forms a heterodimer with NF-IL6 (C/EBPbeta) in vitro; the heterodimeric complex binds to the same DNA sequences as respective homodimers, and CEBPD shows stronger transactivation than NF-IL6 and synergistic transcriptional activation when co-expressed with NF-IL6. In vitro heterodimerization assay, DNA binding (EMSA), transient luciferase reporter assays Proceedings of the National Academy of Sciences of the United States of America High 1741402
1993 CEBPD (C/EBP-delta/NF-IL6-beta) is transcriptionally induced by IL-6 in Hep3B hepatoma cells and becomes the major IL-6-induced protein binding to IL-6 responsive elements (IL-6REs) in nuclei, contrasting with C/EBPbeta (IL-6DBP/NF-IL6) whose activity is modulated post-translationally by IL-6. Nuclear protein binding assays, transient transfection reporter assays, cDNA transfection Nucleic acids research High 7680115
1993 CEBPD protein is induced in nuclei of Hep3B cells after IL-1 treatment and binds the proximal C/EBP site (bZIP1) in the complement C3 promoter; CEBPD trans-activates the C3 promoter in an IL-1-responsive manner, and site-directed mutagenesis of the bZIP1 site significantly reduces basal expression and IL-1 responsiveness. EMSA with antibody supershift, Western immunoblot, co-transfection reporter assay, site-directed mutagenesis Proceedings of the National Academy of Sciences of the United States of America High 8385337
1993 The human CEBPD (C/EBP delta, CRP3, CELF) gene is intronless and maps to the pericentromeric region of human chromosome 8 (8q11), as determined by fluorescence in situ hybridization (FISH) and somatic cell hybrid analysis. FISH, restriction mapping, somatic cell hybrid DNA analysis, sequence analysis Genomics Medium 8314590
1995 CEBPD (NF-IL6-beta/CRP3) physically interacts with the transcription factor PU.1; deletion of the C-terminal 28 amino acids of PU.1 (Ets domain) or deletion of the CEBPD leucine zipper domain disrupts this interaction. PU.1 and CEBPD simultaneously bind adjacent DNA sites and synergistically activate transcription. Far Western blot, cDNA library screen, deletion mutagenesis, EMSA, transient expression transcription assays Journal of immunology High 7594592
1995 Growth hormone (GH) induces CEBPD transcription (not translation) in 3T3-F442A preadipocytes, increasing CEBPD mRNA (superinducible by cycloheximide), in contrast to C/EBPbeta which is regulated at the translational level by GH; this induction is involved in initiating adipocyte differentiation. EMSA with specific antibodies, Western blot, Northern blot, Janus kinase 2 inhibitor treatment Molecular endocrinology Medium 7760844
1996 VIP, PACAP, and noradrenaline induce CEBPD (and C/EBPbeta) mRNA expression in mouse cortical astrocytes via the cAMP second-messenger pathway; CEBPD behaves as a cAMP-inducible immediate-early gene (induced in the presence of protein synthesis inhibitor). Transfection of CEBPD (or active C/EBPbeta) expression vectors enhances glycogen resynthesis elicited by noradrenaline. Northern blot, protein synthesis inhibitor treatment, transfection with expression vectors, glycogen resynthesis assay The Journal of neuroscience Medium 8558260
1997 CEBPD expression is induced in G0-arrested mouse mammary epithelial cells (COMMA D) by serum/growth factor withdrawal or contact inhibition; antisense CEBPD expression markedly delays growth arrest, establishing CEBPD as required for initiation of G0 arrest in mammary epithelial cells. Northern blot, Western blot, EMSA, antisense construct expression, cell cycle analysis The Journal of biological chemistry Medium 9045647
2001 LPS-induced COX-2 mRNA induction in macrophages is biphasic: the first phase requires C/EBPbeta (but not de novo protein synthesis), while the second, sustained phase requires both C/EBPbeta and CEBPD. CEBPD synthesis is dramatically increased by LPS and repressed by combined inhibition of MAPK and SAPK2/p38 cascades. C/EBPbeta knockout macrophages, protein synthesis inhibitors, MAPK inhibitors, Northern blot, functional COX-2 induction assays The Journal of biological chemistry High 11668179
2003 CEBPD protein is ubiquitinated and degraded in a ubiquitin-dependent manner primarily in the nucleus during G0 growth arrest in mouse mammary epithelial cells; the CEBPD mRNA has a short half-life (~35 min) and a short poly(A) tail (~100 nt) with degradation via a deadenylation-independent pathway. Transcriptional inhibitor pulse-chase, oligo/RNase H cleavage, RACE-PAT, proteasome inhibitor experiments The Journal of biological chemistry Medium 12554732
2005 CEBPD transcriptional activity is regulated by the p38 MAP kinase pathway downstream of IL-1beta; a domain between amino acids 70–108 of CEBPD contains both a transactivation region and a docking site for p38 MAP kinase (residues 75–85) required for CEBPD phosphorylation and IL-1-dependent haptoglobin induction. p38 inhibitor (SB203580), mutagenesis of CEBPD domains, transient transfection reporter assays, Northern blot Biochemical and biophysical research communications Medium 15694370
2008 CEBPD is sumoylated at lysine 120 by SUMO1 in HepG2 cells; sumoylated CEBPD recruits HDAC1 and HDAC3 to the PPARG2 promoter, inactivating PPARG2 transcription. Non-sumoylated CEBPD activates PPARG2 transcription via two C/EBP binding motifs (-324/-311 and -158/-145), and excess CEBPD reverses suCEBPD/HDAC1/HDAC3-mediated PPARG2 inactivation to promote hepatic lipogenesis. 5'-serial deletion reporter analysis, ChIP assay, site-directed mutagenesis of CEBPD (K120), co-immunoprecipitation, sumoylation assays Biochimica et biophysica acta High 18619497
2010 CEBPD induces expression of the CDC27 (APC3) subunit of the anaphase-promoting complex/cyclosome (APC/C), leading to polyubiquitination and proteasomal degradation of cyclin D1, and also downregulates cyclin B1, Skp2, and Plk-1. Loss of CEBPD in knockout MEFs reduces Cdc27 and increases cyclin D1 even with activated GSK-3beta. Knockout MEFs, siRNA silencing, ChIP, luciferase reporter, overexpression studies, Western blot Proceedings of the National Academy of Sciences of the United States of America High 20439707
2010 CEBPD mediates nuclear import of FANCD2 by interacting with both FANCD2 and importin 4 (IPO4) via separate domains, forming a FANCD2-IPO4 complex that augments nuclear import of FANCD2—a prerequisite for its monoubiquitination required for DNA repair. This represents a transcription-independent activity of CEBPD in the DNA damage response. Co-immunoprecipitation, gene knockout (CEBPD KO MEFs), siRNA depletion, overexpression, Western blot, nuclear fractionation, mitomycin C survival assays Proceedings of the National Academy of Sciences of the United States of America High 20805509
2010 CEBPD drives expression of pentraxin-3 (PTX3) in astrocytes; PTX3 secreted by CEBPD-activated astrocytes attenuates macrophage-mediated phagocytosis of damaged neuron cells, revealing a role for astrocytic CEBPD in accumulation of damaged neurons. Global gene expression profiling, reporter assay, ChIP, loss-of-function (siRNA), phagocytosis functional assay Neurobiology of aging Medium 21112127
2010 CEBPD trans-activates the SOD1 promoter, reducing cisplatin-induced reactive oxygen species and apoptosis in bladder urothelial carcinoma cells; this represents a novel pro-survival (drug resistance) role for CEBPD through direct transcriptional regulation of SOD1. Reporter assay (promoter transactivation), ChIP, ROS measurement, apoptosis assays, siRNA knockdown Biochemical pharmacology Medium 20385105
2010 CEBPD and STAT-1 are required for TLR8 basal and R848-stimulated transcriptional activity; ChIP assays showed CEBPD and C/EBPbeta bind C/EBP cis-elements in the TLR8 promoter, and R848 stimulation enhances binding of CEBPD (but not C/EBPbeta) to these sites. Reporter gene analysis, ChIP assay, cytokine stimulation The Journal of biological chemistry Medium 20829351
2010 LPS-induced CEBPD expression is inhibited by the HDAC inhibitor trichostatin A (TSA) through reduction of c-Jun recruitment (via Sp1) to the CEBPD promoter. A DAPA and ChIP assay showed that c-Jun is recruited via Sp1 to the CEBPD promoter upon LPS treatment, and TSA represses this recruitment; loss of CEBPD results in increased binding of C/EBPalpha and C/EBPbeta to the COX-2 promoter. Reporter assay (Sp1 site mutagenesis), DAPA, ChIP, Western blot, HDAC inhibitor treatment Journal of cellular biochemistry Medium 20506344
2011 Miz1 is phosphorylated at Ser178 after LPS stimulation, which is required for recruitment of HDAC1 to repress transcription of the CEBPD gene, thereby terminating LPS-induced inflammation. Genetic disruption of the Miz1 POZ domain results in prolonged CEBPD expression and hyperinflammation. Genetic mouse model (Miz1 POZ domain disruption), phosphorylation mapping, HDAC1 recruitment assay, in vivo LPS challenge Nature immunology High 23525087
2011 CEBPD regulates VEGF-C and VEGFR3 expression in lymphatic endothelial cells (LECs) to promote lymphangiogenesis; hypoxia induces CEBPD expression via HIF-1alpha, and CEBPD in turn regulates HIF-1alpha expression. Blocking HIF-1alpha activity abolishes CEBPD-induced VEGF-C and VEGFR3 expression in LECs. Genetic deletion in mice, forced expression/knockdown in LECs, in vitro tube formation, in vivo lymphangiogenesis assay, reporter assay Oncogene Medium 21666710
2012 CEBPD silencing in pancreatic beta-cells exacerbates cytokine-induced apoptosis by increasing CHOP expression and its downstream target BIM; CEBPD overexpression inhibits BIM expression and partially protects beta-cells. CEBPD also hampers IRF-1 upregulation and increases STAT1 activation, boosting production of CXCL1, 9, 10, and CCL20 chemokines when silenced. siRNA knockdown (single and double), overexpression, caspase assays, apoptosis quantification in rat INS-1E, primary rat beta-cells, and human islets PloS one Medium 22347430
2007 CEBPD represses ΔNp63alpha expression in keratinocytes (identified as a primary p63 target by RNAi screening and ChIP); reciprocally, CEBPD binds to and activates the ΔNp63 promoter. CEBPD overexpression alters the normal p63 isoform profile and is found on p63 target gene promoters by ChIP, indicating direct co-regulation. RNAi screening, RT-PCR, ChIP, overexpression in HaCaT and primary keratinocytes BMC molecular biology Medium 17903252
2010 CEBPD reverses RB/E2F1-mediated repression of PPARG2 and GADD153 promoters; increased CEBPD attenuates E2F1-induced cancer cell proliferation. HMDB-induced CEBPD expression is activated through the p38/CREB pathway. ChIP assays demonstrate direct CEBPD binding at PPARG2 and GADD153 promoters. Methylation-specific PCR, reporter assay, ChIP, p38/CREB pathway inhibitors, xenograft mouse model Clinical cancer research Medium 20971808
2016 The EGFR/STAT3 signaling pathway drives cisplatin-induced CEBPD expression in bladder urothelial carcinoma cells; CEBPD in turn directly activates ABCB1 and ABCC2 drug transporter genes (shown by reporter and in vivo DNA-binding assays), conferring cross-resistance to paclitaxel. Loss-of-function of EGFR or STAT3 reduces CEBPD expression. Loss-of-function assays (siRNA/shRNA), reporter assays, in vivo DNA-binding (ChIP), xenograft animal assay, pharmacological inhibitors (gefitinib, S3I-201) Clinical cancer research Medium 27435393
2017 Metformin reduces Src-mediated CEBPD protein degradation and activates AMPK, leading to increased CEBPD expression in hepatocellular carcinoma cells; CEBPD then transcriptionally activates LC3B and ATG3 to induce autophagy and apoptosis. Reporter assay, ChIP, siRNA knockdown, AMPK inhibitor/activator, Western blot, apoptosis assays in Huh7 cells Oncotarget Medium 28099155
2019 DN-ATF5, a dominant-negative leucine zipper peptide, physically associates with CEBPD (and CEBPB) in cells, as revealed by unbiased pulldown assays coupled with mass spectrometry and immunoblotting; DN-ATF5 suppresses CEBPD transcriptional activity and CEBPD knockdown promotes apoptosis in cancer cells but not normal astrocytes. Pull-down assay with mass spectrometry, immunoblotting, knockdown (siRNA), transcriptional reporter assay Molecular cancer research Medium 31676720
2020 Importin 4 (IPO4) augments nuclear translocation of CEBPD via nuclear localization signals (NLS), enabling CEBPD to transcriptionally upregulate PRKDC (DNA-PKcs), which mediates cisplatin-induced DNA damage repair. Knockdown of IPO4 or CEBPD reduces PRKDC expression and enhances cisplatin sensitivity in vitro and in vivo. shRNA knockdown, reporter assay, ChIP, xenograft assay, functional DNA repair assays Oncogene Medium 32661323
2021 BRD4 bromodomain-1 (not bromodomain-2) controls CEBPD expression through a BRD4/CEBPD/promoter/enhancer complex in vascular smooth muscle cells; endogenous BRD4 co-immunoprecipitates with CEBPD, and both co-immunoprecipitate Cebpd promoter and enhancer DNA fragments. BRD4 and CEBPD cooperate to upregulate PDGFRα expression in SMC inflammation. ChIP-seq (H3K27ac/BRD4), genomic deletion, gene silencing (BRD4), Co-IP, loss- and gain-of-function experiments, JQ1 pharmacological inhibition Molecular therapy. Methods & clinical development Medium 33768129
2021 Synthetic CEBPD leucine zipper decoy peptides (Dpep/Bpep) interfere with formation of active CEBPD homodimers and heterodimers, suppressing expression of CEBPD direct targets IL6, IL8, and asparagine synthetase (ASNS), depleting survivin, and elevating BMF to trigger cancer cell apoptosis without affecting non-transformed cells. Cell-penetrating peptide treatment, reporter assay for transcriptional activity, Western blot for target proteins, apoptosis assays, xenograft mouse models Cancers Medium 34065488
2023 In glioblastoma under hypoxia, HIF1α and HIF2α activate the CEBPD promoter; CEBPD then activates the FN1 (fibronectin) promoter (shown by ChIP-seq and luciferase reporter assay), and FN1-integrin receptor interactions promote EGFR phosphorylation activating the EGFR/PI3K pathway, driving invasion. Proteomic analysis, ChIP-seq and ChIP-qPCR, luciferase reporter assay, CEBPD knockdown, Western blot, in vitro and in vivo invasion/growth assays Cell death & disease Medium 37059730
2024 CEBPD acts as a key transcription factor regulating the enhanced function of IL-21-engineered NK cells; CEBPD deletion results in loss of IL-21 NK cell anti-tumor potency, while CEBPD overexpression increases long-term cytotoxicity and metabolic fitness of NK cells. CRISPR-mediated CEBPD deletion, overexpression, chromatin accessibility (ATAC-seq), multiple in vivo GBM models, cytotoxicity assays Cancer cell Medium 39137729
2011 CEBPD suppresses prolactin (PRL) promoter activity by 96% and inhibits cell proliferation in PRL-secreting pituitary tumor cells; CEBPD interacts with the transcription factor Pit1, and they attenuate each other's binding to the PRL promoter. CEBPD also suppresses c-Myc, survivin, and cyclins B1, B2, and D1. siRNA knockdown, forced expression, ChIP for PRL promoter binding, reporter assay, microarray expression profiling Molecular endocrinology Medium 21980073
2014 Androgen receptor (AR) directly binds to the CEBPD promoter region upon androgen stimulation and activates CEBPD transcription in prostate cancer cells; SUZ12 and EZH2 attenuate androgen-induced CEBPD transcription. CEBPD in turn directly binds and activates the CASP8 (caspase 8) promoter. Reporter assay, ChIP (in vivo DNA-binding assay), overexpression/knockdown studies, functional apoptosis assay Cell death & disease Medium 24810056
2021 In glioma, SUMOylation of PUM2 (by UBE2I/SUMO2/3) reduces PUM2's inhibitory effect on CEBPD mRNA, increasing CEBPD expression; CEBPD then binds the upstream promoter region of DSG2 and upregulates its expression to promote vasculogenic mimicry. Interactions were confirmed by Co-IP (PUM2 sumoylation), RIP assay (PUM2-CEBPD mRNA), and ChIP/luciferase (CEBPD-DSG2 promoter). Co-IP, immunofluorescence, RIP assay, ChIP assay, luciferase reporter assay, siRNA knockdown, 3D cell culture (vasculogenic mimicry assay) Clinical and translational medicine Medium 32997416
2021 In cancer-associated fibroblasts, cisplatin and 5-fluorouracil induce CEBPD expression; CEBPD transcriptionally activates SDF4 (stromal-cell-derived factor 4), which interacts with CXCR4 to trigger VEGFD expression via ERK1/2 and p38 pathways in endothelial cells, promoting tumor angiogenesis. ChIP assay, reporter assay, Co-IP (SDF4-CXCR4 interaction), siRNA knockdown, in vitro tube formation, in vivo angiogenesis assay Cell death discovery Medium 33953165

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2008 A postnatal switch of CELF and MBNL proteins reprograms alternative splicing in the developing heart. Proceedings of the National Academy of Sciences of the United States of America 427 19075228
2001 The CELF family of RNA binding proteins is implicated in cell-specific and developmentally regulated alternative splicing. Molecular and cellular biology 370 11158314
1992 A member of the C/EBP family, NF-IL6 beta, forms a heterodimer and transcriptionally synergizes with NF-IL6. Proceedings of the National Academy of Sciences of the United States of America 313 1741402
2011 The importance of CELF control: molecular and biological roles of the CUG-BP, Elav-like family of RNA-binding proteins. Wiley interdisciplinary reviews. RNA 195 22180311
2015 Antagonistic regulation of mRNA expression and splicing by CELF and MBNL proteins. Genome research 162 25883322
1993 The two C/EBP isoforms, IL-6DBP/NF-IL6 and C/EBP delta/NF-IL6 beta, are induced by IL-6 to promote acute phase gene transcription via different mechanisms. Nucleic acids research 161 7680115
2010 Induction of neutrophil gelatinase-associated lipocalin expression by co-stimulation with interleukin-17 and tumor necrosis factor-alpha is controlled by IkappaB-zeta but neither by C/EBP-beta nor C/EBP-delta. The Journal of biological chemistry 134 20220144
1993 Participation of the transcription factor C/EBP delta in the acute-phase regulation of the human gene for complement component C3. Proceedings of the National Academy of Sciences of the United States of America 133 8385337
2005 Mammalian CELF/Bruno-like RNA-binding proteins: molecular characteristics and biological functions. Biochimie 127 16480813
2001 The induction of cyclooxygenase-2 mRNA in macrophages is biphasic and requires both CCAAT enhancer-binding protein beta (C/EBP beta ) and C/EBP delta transcription factors. The Journal of biological chemistry 124 11668179
1997 The processive endocellulase CelF, a major component of the Clostridium cellulolyticum cellulosome: purification and characterization of the recombinant form. Journal of bacteriology 113 8981979
1995 Multiple proteins physically interact with PU.1. Transcriptional synergy with NF-IL6 beta (C/EBP delta, CRP3). Journal of immunology (Baltimore, Md. : 1950) 95 7594592
2003 Antagonistic regulation of alpha-actinin alternative splicing by CELF proteins and polypyrimidine tract binding protein. RNA (New York, N.Y.) 92 12649496
1996 Vasoactive intestinal peptide, pituitary adenylate cyclase-activating peptide, and noradrenaline induce the transcription factors CCAAT/enhancer binding protein (C/EBP)-beta and C/EBP delta in mouse cortical astrocytes: involvement in cAMP-regulated glycogen metabolism. The Journal of neuroscience : the official journal of the Society for Neuroscience 90 8558260
1995 Early responses of trans-activating factors to growth hormone in preadipocytes: differential regulation of CCAAT enhancer-binding protein-beta (C/EBP beta) and C/EBP delta. Molecular endocrinology (Baltimore, Md.) 81 7760844
2009 MBNL and CELF proteins regulate alternative splicing of the skeletal muscle chloride channel CLCN1. Nucleic acids research 80 19720736
2004 CELF6, a member of the CELF family of RNA-binding proteins, regulates muscle-specific splicing enhancer-dependent alternative splicing. The Journal of biological chemistry 77 14761971
1997 CCAAT/enhancer-binding protein-delta (C/EBP-delta) is induced in growth-arrested mouse mammary epithelial cells. The Journal of biological chemistry 76 9045647
2010 CCAAT/enhancer binding protein delta (CEBPD) elevating PTX3 expression inhibits macrophage-mediated phagocytosis of dying neuron cells. Neurobiology of aging 73 21112127
2024 Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD. Cancer cell 71 39137729
2013 Suppression of inflammation and acute lung injury by Miz1 via repression of C/EBP-δ. Nature immunology 71 23525087
2008 Posttranscriptional regulation of gene networks by GU-rich elements and CELF proteins. RNA biology 70 18971639
2005 Cardiac tissue-specific repression of CELF activity disrupts alternative splicing and causes cardiomyopathy. Molecular and cellular biology 69 15988035
2011 C/EBP-δ regulates VEGF-C autocrine signaling in lymphangiogenesis and metastasis of lung cancer through HIF-1α. Oncogene 67 21666710
2010 C/EBP{delta} targets cyclin D1 for proteasome-mediated degradation via induction of CDC27/APC3 expression. Proceedings of the National Academy of Sciences of the United States of America 65 20439707
2012 CUG-BP, Elav-like family (CELF)-mediated alternative splicing regulation in the brain during health and disease. Molecular and cellular neurosciences 61 23247071
2003 Keratinocyte growth factor and the transcription factors C/EBP alpha, C/EBP delta, and SREBP-1c regulate fatty acid synthesis in alveolar type II cells. The Journal of clinical investigation 58 12865412
2017 Metformin promotes apoptosis in hepatocellular carcinoma through the CEBPD-induced autophagy pathway. Oncotarget 57 28099155
2010 Transcriptional up-regulation of SOD1 by CEBPD: a potential target for cisplatin resistant human urothelial carcinoma cells. Biochemical pharmacology 57 20385105
2016 Inhibition of the EGFR/STAT3/CEBPD Axis Reverses Cisplatin Cross-resistance with Paclitaxel in the Urothelial Carcinoma of the Urinary Bladder. Clinical cancer research : an official journal of the American Association for Cancer Research 56 27435393
2023 CEBPD is a master transcriptional factor for hypoxia regulated proteins in glioblastoma and augments hypoxia induced invasion through extracellular matrix-integrin mediated EGFR/PI3K pathway. Cell death & disease 54 37059730
2012 The transcription factor C/EBP delta has anti-apoptotic and anti-inflammatory roles in pancreatic beta cells. PloS one 54 22347430
2002 C/EBP-beta, C/EBP-delta, PU.1, AML1 genes: mutational analysis in 381 samples of hematopoietic and solid malignancies. Leukemia research 50 11916518
2017 Ancient antagonism between CELF and RBFOX families tunes mRNA splicing outcomes. Genome research 49 28512194
2016 Conserved functional antagonism of CELF and MBNL proteins controls stem cell-specific alternative splicing in planarians. eLife 47 27502555
2013 Position-dependent and neuron-specific splicing regulation by the CELF family RNA-binding protein UNC-75 in Caenorhabditis elegans. Nucleic acids research 47 23416545
2008 HDAC1/HDAC3 modulates PPARG2 transcription through the sumoylated CEBPD in hepatic lipogenesis. Biochimica et biophysica acta 46 18619497
1999 Cellobiose-6-phosphate hydrolase (CelF) of Escherichia coli: characterization and assignment to the unusual family 4 of glycosylhydrolases. Journal of bacteriology 46 10572139
2010 CEBPD reverses RB/E2F1-mediated gene repression and participates in HMDB-induced apoptosis of cancer cells. Clinical cancer research : an official journal of the American Association for Cancer Research 44 20971808
2005 Identification of CELF splicing activation and repression domains in vivo. Nucleic acids research 41 15894795
1996 Molecular study and overexpression of the Clostridium cellulolyticum celF cellulase gene in Escherichia coli. Microbiology (Reading, England) 40 8936327
2013 CELF family RNA-binding protein UNC-75 regulates two sets of mutually exclusive exons of the unc-32 gene in neuron-specific manners in Caenorhabditis elegans. PLoS genetics 39 23468662
2019 Dominant-Negative ATF5 Compromises Cancer Cell Survival by Targeting CEBPB and CEBPD. Molecular cancer research : MCR 38 31676720
1996 Effect of thermal injury on the expression of transcription factors that regulate acute phase response genes: the response of C/EBP alpha, C/EBP beta, and C/EBP delta to thermal injury. Surgery 38 8650608
2010 The role of CELF proteins in neurological disorders. RNA biology 36 20622515
2010 CCAAT/enhancer binding protein delta (C/EBPdelta, CEBPD)-mediated nuclear import of FANCD2 by IPO4 augments cellular response to DNA damage. Proceedings of the National Academy of Sciences of the United States of America 35 20805509
2020 SUMOylation of PUM2 promotes the vasculogenic mimicry of glioma cells via regulating CEBPD. Clinical and translational medicine 34 32997416
1991 Nucleotide sequence of the cellulase gene celF of Clostridium thermocellum. Research in microbiology 33 1805307
2015 ROCK2 promotes HCC proliferation by CEBPD inhibition through phospho-GSK3β/β-catenin signaling. FEBS letters 32 25771860
2009 The neurofibromatosis type I pre-mRNA is a novel target of CELF protein-mediated splicing regulation. Nucleic acids research 32 19854948
1993 The human C/EBP delta (CRP3/CELF) gene: structure and chromosomal localization. Genomics 32 8314590
2021 Cell-Penetrating CEBPB and CEBPD Leucine Zipper Decoys as Broadly Acting Anti-Cancer Agents. Cancers 31 34065488
2016 CELF RNA binding proteins promote axon regeneration in C. elegans and mammals through alternative splicing of Syntaxins. eLife 31 27253061
2016 MiR-193b Mediates CEBPD-Induced Cisplatin Sensitization Through Targeting ETS1 and Cyclin D1 in Human Urothelial Carcinoma Cells. Journal of cellular biochemistry 31 27918099
2011 The CCAAT/enhancer binding protein (C/EBP) δ is differently regulated by fibrillar and oligomeric forms of the Alzheimer amyloid-β peptide. Journal of neuroinflammation 31 21492414
2010 C/EBP{delta} and STAT-1 are required for TLR8 transcriptional activity. The Journal of biological chemistry 31 20829351
2021 CELF Family Proteins in Cancer: Highlights on the RNA-Binding Protein/Noncoding RNA Regulatory Axis. International journal of molecular sciences 30 34681716
2020 Inhibiting Importin 4-mediated nuclear import of CEBPD enhances chemosensitivity by repression of PRKDC-driven DNA damage repair in cervical cancer. Oncogene 30 32661323
2018 Transcription factors Tp73, Cebpd, Pax6, and Spi1 rather than DNA methylation regulate chronic transcriptomics changes after experimental traumatic brain injury. Acta neuropathologica communications 30 29482641
2021 Fibroblast CEBPD/SDF4 axis in response to chemotherapy-induced angiogenesis through CXCR4. Cell death discovery 29 33953165
2015 Multiple Protein Kinases via Activation of Transcription Factors NF-κB, AP-1 and C/EBP-δ Regulate the IL-6/IL-8 Production by HIV-1 Vpr in Astrocytes. PloS one 29 26270987
2012 Artemisinic acid is a regulator of adipocyte differentiation and C/EBP δ expression. Journal of cellular biochemistry 29 22396222
2010 CELF proteins regulate CFTR pre-mRNA splicing: essential role of the divergent domain of ETR-3. Nucleic acids research 27 20631008
2007 Cloning and embryonic expression patterns of the chicken CELF family. Developmental dynamics : an official publication of the American Association of Anatomists 27 17584860
1996 Nuclear factor kappa B (NF-kappa B), nuclear factor interleukin-6 (NFIL-6 or C/EBP beta) and nuclear factor interleukin-6 beta (NFIL6-beta or C/EBP delta) are not sufficient to activate the endogenous interleukin-6 gene in the human breast carcinoma cell line MCF-7. Comparative analysis with MDA-MB-231 cells, an interleukin-6-expressing human breast carcinoma cell line. European journal of biochemistry 27 8774705
1995 Mouse chromosomal location of the CCAAT/enhancer binding proteins C/EBP beta (Cebpb), C/EBP delta (Cebpd), and CRP1 (Cebpe). Genomics 27 8530045
2014 ABLIM1 splicing is abnormal in skeletal muscle of patients with DM1 and regulated by MBNL, CELF and PTBP1. Genes to cells : devoted to molecular & cellular mechanisms 26 25403273
2007 Reciprocal regulation of p63 by C/EBP delta in human keratinocytes. BMC molecular biology 26 17903252
2003 Posttranscriptional and posttranslational regulation of C/EBP delta in G0 growth-arrested mammary epithelial cells. The Journal of biological chemistry 26 12554732
2014 The combination of the prodrugs perforin-CEBPD and perforin-granzyme B efficiently enhances the activation of caspase signaling and kills prostate cancer. Cell death & disease 25 24810056
2023 Targeting Transcription Factors ATF5, CEBPB and CEBPD with Cell-Penetrating Peptides to Treat Brain and Other Cancers. Cells 23 36831248
2021 A hierarchical and collaborative BRD4/CEBPD partnership governs vascular smooth muscle cell inflammation. Molecular therapy. Methods & clinical development 23 33768129
2021 CEBPD Potentiates the Macrophage Inflammatory Response but CEBPD Knock-Out Macrophages Fail to Identify CEBPD-Dependent Pro-Inflammatory Transcriptional Programs. Cells 23 34571881
2020 Shikonin inhibits CEBPD downregulation in IL‑17‑treated HaCaT cells and in an imiquimod‑induced psoriasis model. Molecular medicine reports 23 32705251
2005 IL-1 beta-dependent regulation of C/EBP delta transcriptional activity. Biochemical and biophysical research communications 23 15694370
2009 C/EBP beta and C/EBP delta expression is elevated in the early phase of ethanol-induced hepatosteatosis in mice. Acta pharmacologica Sinica 22 19617893
2021 Exosomal microRNA let-7-5p from Taenia pisiformis Cysticercus Prompted Macrophage to M2 Polarization through Inhibiting the Expression of C/EBP δ. Microorganisms 21 34209741
2010 Differential expression of the Brunol/CELF family genes during Xenopus laevis early development. The International journal of developmental biology 21 19757395
2007 The Cebpd (C/EBPdelta) gene is induced by luteinizing hormones in ovarian theca and interstitial cells but is not essential for mouse ovary function. PloS one 21 18092000
2003 Expression pattern of the CCAAT/enhancer-binding proteins C/EBP-alpha, C/EBP-beta and C/EBP-delta in the human placenta. Virchows Archiv : an international journal of pathology 21 14691721
2012 Repression of nuclear CELF activity can rescue CELF-regulated alternative splicing defects in skeletal muscle models of myotonic dystrophy. PLoS currents 20 22453899
2011 CEBPD suppresses prolactin expression and prolactinoma cell proliferation. Molecular endocrinology (Baltimore, Md.) 20 21980073
2007 Expression of MBNL and CELF mRNA transcripts in muscles with myotonic dystrophy. Neuromuscular disorders : NMD 20 17331722
2020 MiR-324-5p/PTPRD/CEBPD axis promotes papillary thyroid carcinoma progression via microenvironment alteration. Cancer biology & therapy 18 32151175
2018 Gemcabene, a first-in-class lipid-lowering agent in late-stage development, down-regulates acute-phase C-reactive protein via C/EBP-δ-mediated transcriptional mechanism. Molecular and cellular biochemistry 18 29644527
2010 CCAAT/Enhancer Binding Protein-delta (C/EBP-delta) regulates cell growth, migration and differentiation. Cancer cell international 18 21143913
2009 Induction of CRP3/MLP expression during vein arterialization is dependent on stretch rather than shear stress. Cardiovascular research 18 19351738
2008 CELF-mediated alternative splicing is required for cardiac function during early, but not later, postnatal life. Journal of molecular and cellular cardiology 18 19073192
2000 CYP2B1 is regulated by C/EBP alpha and C/EBP delta inlung epithelial cells. Molecular cell biology research communications : MCBRC 18 10683316
1998 Crystallization of the catalytic domain of Clostridium cellulolyticum CeLF cellulase in the presence of a newly synthesized cellulase inhibitor. Acta crystallographica. Section D, Biological crystallography 18 9761829
2018 Cebpd Is Essential for Gamma-Tocotrienol Mediated Protection against Radiation-Induced Hematopoietic and Intestinal Injury. Antioxidants (Basel, Switzerland) 17 29642403
1999 Local signals induce CCAAT/enhancer binding protein-delta (C/EBP-delta) and C/EBP-beta mRNA expression in the involuting mouse mammary gland. Breast cancer research and treatment 17 10634518
2024 The role of CELF family in neurodevelopment and neurodevelopmental disorders. Neurobiology of disease 16 38729272
2017 C/EBP-δ positively regulates MDSC expansion and endothelial VEGFR2 expression in tumor development. Oncotarget 16 28881585
2003 CelF of Orpinomyces PC-2 has an intron and encodes a cellulase (CelF) containing a carbohydrate-binding module. Applied biochemistry and biotechnology 16 12721415
2011 Expression of a dominant negative CELF protein in vivo leads to altered muscle organization, fiber size, and subtype. PloS one 15 21541285
2022 Angiogenesis Driven by the CEBPD-hsa-miR-429-VEGFA Signaling Axis Promotes Urothelial Carcinoma Progression. Cells 14 35203290
2021 High-Throughput Screening for CEBPD-Modulating Compounds in THP-1-Derived Reporter Macrophages Identifies Anti-Inflammatory HDAC and BET Inhibitors. International journal of molecular sciences 14 33809617
2021 Biological significance of MYC and CEBPD coamplification in urothelial carcinoma: Multilayered genomic, transcriptional and posttranscriptional positive feedback loops enhance oncogenic glycolysis. Clinical and translational medicine 14 34954904
2010 Inhibition of LPS-induced C/EBP delta by trichostatin A has a positive effect on LPS-induced cyclooxygenase 2 expression in RAW264.7 cells. Journal of cellular biochemistry 13 20506344

Missed literature

Know a paper Affinage missed for CEBPD? Flag it for the maintainers and the community.

No submissions yet.